CD4 and lymphoma: Research demonstrated that anti-CD20 mAb, such as rituximab, could achieve a long-lasting “vaccinal effect” with the presence of both CD4+ and CD8+ T cells [57, 58], indicating the potential value of QHF as an add-on therapy to the R-based therapy for lymphoma patients.